Navigation Links
Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update
Date:2/21/2012

DSMB) met for the fifth time to review the available safety data and recommended the study continue without change.  VISTA-16 is a Phase 3 pivotal clinical study evaluating the benefit of early varespladib treatment in high-risk ACS patients.  As per a Special Protocol Assessment with FDA, the primary endpoint of the VISTA-16 study is a reduction in Major Adverse Cardiovascular Events (MACE) as defined by FDA draft guidance to include cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or documented unstable angina with objective evidence of ischemia requiring hospitalization.  Details regarding the study can be found at http://www.clinicaltrials.gov.
  • In the fourth quarter of 2011, the VISTA-16 study accrued the requisite one hundred and ninety-three (193) adjudicated primary endpoint events required for the pre-specified interim efficacy analysis.  Subsequent to the end of the fourth quarter, the DSMB scheduled a meeting for the second week in March 2012 to review all available safety data and to conduct the formal interim efficacy analysis.  The interim efficacy analysis plan for the VISTA-16 clinical study allows for a recommendation by the DSMB to stop the study should there be sufficient evidence of overwhelming treatment benefit in the varespladib arm after approximately 193 of the primary events have been accrued.  Overwhelming benefit is defined as a treatment effect in favor of the varespladib arm resulting in a p-value of less than 0.001 (p<0.001).
  • Enrollment in the Phase 2b PEARL-SC clinical study was completed (N=547) in the fourth quarter. The PEARL-SC study is examining the therapeutic benefit of monthly and weekly subcutaneous doses of blisibimod in patients with lupus.  The primary endpoint of PEARL-SC requires patients to demonstrate a greater than or equal to five (>/=5) point reduction in the SELENA-SLEDAI clinical assessment s
    '/>"/>

  • SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
    2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
    3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... DALLAS , September 17, 2014 ... Electronics Market by Component (Sensor, Battery, Memory Device, Display, ... and Fitness & Wellness), and by Geography - Global ... of medical electronics market is expected to reach $56.50 ... from 2014 to 2020. Browse 235 market ...
    (Date:9/17/2014)... 2014  NuView Life Sciences, Inc. (NuView) announced ... agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) to ... biomarker to detect cancers of the breast and ... diagnostic-imaging applications. NuView retains all rights for the ... urine screen applications. Under the terms ...
    (Date:9/17/2014)... Isis Pharmaceuticals, Inc. (NASDAQ: ... $4 million milestone payment from Achaogen, Inc. (NASDAQ: ... of a Phase 3 study of plazomicin in ... infections.  The Phase 3 study is designed as ... safety of plazomicin compared to colistin in patients ...
    Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
    ... Belt Technologies, Inc., a Pittsburgh based medical device company ... use in orthopaedic and neurosurgery procedures, has closed on ... financing. The round was led by private investors ... Works (Pittsburgh) and consisted of both new investments and ...
    ... Sept. 30 Law firm Clifford Chance, as international counsel, ... with Wyeth under China,s Anti-Monopoly Law. The clearance was issued ... , Competition approval from the Chinese authorities was one of ... The EU has already approved the deal; decisions are awaited ...
    Cached Medicine Technology:Blue Belt Technologies, Inc. Closes Series A Financing 2Blue Belt Technologies, Inc. Closes Series A Financing 3Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth 2
    (Date:9/17/2014)... (PRWEB) September 17, 2014 In Pretrial ... that “bi-weekly telephonic discovery conferences would be beneficial in ... conferences through mid-December. “At the end of December,” the ... the need for additional conferences. , “The plain ... that there is still much to be discussed as ...
    (Date:9/17/2014)... 2014 (HealthDay News) -- Positive messages about the health ... the habit, a new study suggests. Although smokers ... "loss-framed" messages about the harmful effects of smoking, researchers ... want benefit more from "gain-framed," or positive, messages about ... concluded that using a mix of both types of ...
    (Date:9/17/2014)... Many countries choose to kill all infected poultry ... number of poultry exceeds 10 billion in China. Epidemic ... huge losses. Therefore, it is quite necessary to immunize ... vaccines have been used for more than 10 years ... use H5N1 avian influenza vaccines voluntarily 10 years ago ...
    (Date:9/17/2014)... (PRWEB) September 17, 2014 StartX ... revealed 12 companies raising rounds of funding at its ... few hundred investors and media, was the first such ... located next to the university. The presentations were delivered ... adjacent to StartX-QB3 Labs, a 2,000 square foot life ...
    (Date:9/17/2014)... The Delta Dental Community Care Foundation announced today ... Health Foundation: America’s ToothFairy (NCOHF) to support oral health ... Zone Program® in California. , The Orange County NCOHF ... local constituent groups and stakeholders in a comprehensive approach ... its devastating effects on local families. The support of ...
    Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:Delta Dental Community Care Foundation Donation to America's ToothFairy Helps Deliver Critical Services 2
    ... multi-center U.S. registry on the efficacy of carotid stenting ... are at high risk for standard surgical therapy.// ... CAPTURE (Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare ... Cardiology’s 55th Annual Session in Atlanta. The multi-center study ...
    ... with a friend will be more beneficial to health than ... Elizabeth Gould at Harvard University compared the costs and benefits ... and found that contrary to accepted wisdom, jogging was not ... Daily Mail. ,The researchers carried out series of ...
    ... Hopkins University School of Medicine said that genetic material in ... // , The researchers feel that it very ... of mutated human genes. ,Jef Boeke described about ... the yeast cells which is necessary for the stability of ...
    ... spells doom for global economic growth. According to bank economist ... a dent of two to six percentage out of global ... rate reductions and older populations, which will lead to continued ... Burns, has been getting Bay Street and investors to gear ...
    ... at the end of the tunnel. Those infected with human ... workplaces. // Employers will have to face legal charges if ... ,HIV causes acquired immune deficiency syndrome. The ministry of ... of HIV/AIDS, which will seek to protect the rights of ...
    ... and 170 suspected cases of meningococcimia or meningitis in New ... who are taking strict measures to check the spread of ... sure that family members and neighbors of infected persons are ... also distributing leaflets to educate people about the symptoms of ...
    Cached Medicine News:Health News:Carotid Stenting Can Help Patients With Silent Disease 2Health News:Carotid Stenting Can Help Patients With Silent Disease 3Health News:Carotid Stenting Can Help Patients With Silent Disease 4
    ... anesthesia workstation provides an intelligent approach ... to provide true clinical benefits to ... the art computer technology integrates hemodynamic ... color touchscreen display panel. The open ...
    ... Cost effective technology in anesthesia., ,Whether ... manual ventilation, the operating theater or as ... integrated monitoring, the Aliseo product family allows ... ,With three product models, you have ...
    ... in facilities where space is a premium ... gas delivery technologies with an ergonomic and ... functionality of the Draeger Infinity patient monitoring ... workplace environment that is a sound investment ...
    ... A new level of excellence and ... advanced anesthesia delivery system with basic ventilation ... industry leading excellence of the Aestiva/5 Anesthesia ... compact design - it features a configurable ...
    Medicine Products: